Search results
Added:
10 months ago
Source:
Radcliffe Cardiology
A new nationwide cohort study from France suggests that a simple risk stratification tool based on administrative data could help tailor cardiologist follow-up for patients with heart failure (HF), potentially improving survival and optimising resource use. The study found that 40% of patients with HF do not have an annual cardiology consultation, regardless of their disease severity.¹The French…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
Natriuretic peptides are key biomarkers used to risk-stratify patients with heart failure (HF), but current guideline thresholds do not typically account for body mass index (BMI).¹ A new pooled analysis suggests that these fixed thresholds may underestimate risk in patients with HF and higher BMI, questioning the one-size-fits-all approach.²This study was a participant-level pooled analysis of…
View more
Lipoprotein(a): A Risk Factor and Biomarker in Heart Failure
Added:
1 month ago
Review Article
Added:
1 year ago
ESC HF 25 - Findings from a French nationwide cohort study investigating cardiologist follow-up show greater reduction in all-cause mortality associated with annual cardiology hospital visits.Dr Guillaume Baudry (University Hospital of Brabois, Nancy, FR) discusses findings from a nationwide trial investigating the prognostic value of heart failure stratification and cardiologist follow-up in…
View more
Added:
9 months ago
Source:
Radcliffe Cardiology, Mirjam Boros
The global burden of heart failure (HF) remains a significant challenge for healthcare systems.² While clinical risk factors are well-established, the utility of genetic information in predicting incident HF has been less certain. A recent study investigated the ability of a heart failure polygenic risk score (HF PRS) to predict new-onset HF in individuals across the full spectrum of…
View more
Heart Disease in Pregnancy: Maternal and Neonatal Risk
Added:
5 months ago
Original Research
Added:
8 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type…
View more
TAVR is Ready for Most Low-risk Patients
Added:
1 year ago
Review Article
Added:
1 year ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure…
View more
Added:
1 week ago
Dr Lin Yee Chen (University of Minnesota Medical School, Minneapolis, MN, US) joins us to examine which artificial intelligence (AI) applications in heart failure are ready for clinical use today, and which remain experimental. As AI moves from research settings into the clinic, separating genuine clinical utility from hype has become a pressing question for heart failure specialists.In this…
View more